Ключевые слова:
почки, химиотерапия, почечная недостаточность, нефротоксичностьБиблиографические ссылки
Бурнашева Е.В, Шатохин Ю.В, Снежко И.В, Мацуга А.А. Поражение почек при противоопухолевой терапии // Нефрология. 2018;22(5):1 7-24.
Дорохина Е.И., Магомедова А.У., Куликов С.М. и др. Отдаленная нефротоксичность высокодозной химиотерапии по модифицированной программе NHLBFM-90 у взрослых больных диффузной В-крупноклеточной лимфомой // Гематология и трансфузиология. 2016; 61(4):177-183.
Колина И.Б., Бобкова И.Н. Нефропатии при злокачественных новообразованиях (лекция) // Альманах клинической медицины. 2016; 30: 108- 116.
Perazella MA, Berns JS, Rosner MH. Cancer and the Kidney: The Growth of Onco-nephrology. Adv Chronic Kidney Dis 2014;21(1):4-6. doi: 10.10 53/j.ackd.2013.09.002
Shirali AC, Perazella MA. Tubulointerstitial Injury Associated With Chemotherapeutic Agents. Adv Chronic Kidney Dis 2014; 21(1):56-63. doi: 10. 1053/j.ackd.2013.06.010
Wilson FP, Berns JS. Tumor Lysis Syndrome: New Challenges and Recent Advances. Adv Chronic Kidney Dis 2014;21(1):16-26. doi: 10.1053 /j.ackd.2013.07.001
Luciano RL, Brewster UC. Kidney Involvement in Leukemia and Lymphoma. Adv Chronic Kidney Dis 2014;21(1):27-35. doi: 10.1053/j.ackd.2013. 07.004
Jhaveri KD, Shah HH, Patel C et al. Glomerular Diseases Associated With Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Adv Chronic Kidney Dis 2014;21(1): 48-55. doi: 10.1 053/j.ackd.2013.08.003
Blind A. D. Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio-and Chemotherapy //ClinicalTrials. gov Identifier: NCT03480971 First Posted: March. – 2018. – Т. 29. Рр. 101-108
Džidić-Krivić A, Sher EK, Kusturica J, Farhat EK, Nawaz A, Sher F. Unveiling drug induced nephrotoxicity using novel biomarkers and cutting-edge preventive strategies. Chem Biol Interact. 2024 Jan 25;388:110838. doi: 10.1016/j.cbi.2023.110838. Epub 2023 Dec 16. PMID: 38104745.
Akilesh S, Juaire N, Duffield JS. et al Chronic Ifosfamide Toxicity: Kidney Pathology and Pathophysiology. Am J Kidney Dis 2014; 63(5):843-850. doi: 10.1053/j.ajkd.2013.11.028
Hałka J, Spaleniak S, Kade G, Antosiewicz S, Sigorski D. The nephrotoxicity of drugs used in causal oncological therapies. Current Oncol: 2022, 29(12), рр. 9681–9694
Antognini N, Portman R, Dong V, Webb NJ, Chand DH. Detection, monitoring, and mitigation of drug-induced nephrotoxicity: a pragmatic approach. Ther Innov Regul Sci 58(2), 2024 :286–302
Martinez-Castelao A, Gorriz JL, Bover J et al. Consensus document for the detection and management of chronic kidney disease. Nefrologia 2014;34(2):243-262.
Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2023. p.46 PMID: 33232037.
Волкова М. И. и др. Токсичность и безопасность комбинации ленватиниба с пембролизумабом у больных распространенным почечноклеточным раком //Современная онкология. – 2024. – Т. 26. – №. 1. – С. 38-46.
Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res 10(12):4151 –4164
Aapro M, Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2012;38: 235- 240. doi: 10.1016/j. ctrv.2011.05.001
Campbell GA, Hu D, Okusa MD. Acute Kidney Injury in the Cancer Patient. Adv Chronic Kidney Dis 2014;21(1):64-71. doi: 10.1053/j.ackd.2013.08. 002
Finkel M, Goldstein A, Steinberg Y et al. Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012. Pediatr Nephrol 2014;29:2421–2424. doi: 10.1007/s00467-014-2935-z
Oripova, N. A. Modern concepts of the structure and function of Peyer's patches / N. A. Oripova // New Day in Medicine. – 2021. – No. 1(33). – P. 189-193. – EDN XXOSOX.
Awdishu L, Atilano-Roque A, Tuey S, Joy MS. Identification of novel biomarkers for predicting kidney injury due to drugs using “Omic” strategies. Pharmgenomics Pers Med 13, 2020:рр. 687–705